SAE Inhibitor Compounds for Selective Sumoylation Modulation in Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is an urgent need to identify compounds with potent activity targeting SAE (SUMO activating enzyme) to address overexpression associated with poor prognosis in certain cancer patients and modulate sumoylation for therapeutic benefits.
Innovation Solution
Development of a compound of general formula (1) or its isomers, crystalline forms, pharmaceutically acceptable salts, hydrates, or solvates, which exhibit strong inhibitory activity against SAE, potentially used in treating or preventing diseases related to SAE protein, particularly cancer.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If SAE is overexpressed, then sumoylation activity increases, but cancer prognosis deteriorates
Solution Approach 1:
The patent identifies and extracts the critical function of SAE in sumoylation pathways, isolating it as the primary therapeutic target. By focusing on SAE inhibition rather than addressing multiple proteins simultaneously, the patent achieves selective disruption of malignant sumoylation while preserving benign functions.
Solution Approach 2:
The patent employs compounds that alter the functional parameters of SAE through inhibition, changing its catalytic activity toward SUMO activation. This parameter change transforms SAE from a hyperactive state (associated with cancer) to an inactive or reduced-activity state, thereby improving prognosis.
2Reliability
If SAE inhibition is achieved, then sumoylation is modulated for therapeutic benefit, but compound identification challenge increases
Solution Approach 1:
The patent applies local quality by designing compounds with specific structural features tailored to interact with particular residues in the SAE active site. The compounds exhibit selective affinity for the SAE enzyme's catalytic domain, achieving localized inhibition without affecting other cellular processes.
Solution Approach 2:
The patent replaces complex proteomic analysis methods with direct enzymatic assays that measure SAE activity and compound inhibition effects. This substitution simplifies the detection and measurement process by focusing on the specific enzymatic function rather than analyzing multiple proteins simultaneously.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compound effectively inhibits SAE, offering therapeutic potential for treating or preventing cancers such as hematologic cancers and solid tumors by modulating sumoylation pathways.
Implementation Method 1
The present disclosure provides a compound of general formula (1) or an isomer thereof... which exhibit strong inhibitory activity against SAE
Data Source
AI summary
Disclosed in the present disclosure are compounds as SUMO activating enzyme inhibitors. Specifically, the present disclosure relates to a compound of general formula (1), a method for preparing same, and use of the compound of general formula (1) and isomers, crystalline forms, pharmaceutically acceptable salts, hydrates or solvates thereof as SAE inhibitors. The compound and the isomer thereof, the crystalline form thereof, the pharmaceutically acceptable salt thereof, the hydrate thereof, or the solvate thereof of the present disclosure can be used in preparing a medicament for treating or preventing a disease related to SAE protein.